Literature DB >> 8738621

Norepinephrine contents of human prostatic hyperplasia: differences between pathological subtypes.

M Ishigooka1, S Hayami, M Tomaru, T Hashimoto, I Sasagawa, T Nakada.   

Abstract

Tissue norepinephrine content in benign prostatic hyperplasia (BPH) was evaluated to detect possible histological differences in BPH subtypes and to investigate the correlation between norepinephrine levels and age, prostatic weight and clinical symptom score, respectively. Specimens were obtained from 28 patients who underwent transurethral resection of the prostate. Pathologically, 18 out of 28 specimens were classified as fibromyoadenomatous hyperplasia and the remaining 10 as fibromuscular type. Norepinephrine content in the fibromyoadenomatous type was 133.1 +/- 23.1 ng/g, whereas it was 340.3 +/- 60.5 ng/g in the fibromuscular type. Norepinephrine level in the former group was significantly lower than that in the latter group (p < 0.001). In both groups, there was no correlation between norepinephrine content, age and clinical symptom score, while the norepinephrine content had a reverse correlation with prostatic weight only in the former group (p < 0.05). In conclusion, norepinephrine levels were dependent upon histological differences, especially upon the amount of smooth muscle elements, in the evaluated specimen. Severity of prostatism and patients' age showed no correlation with tissue norepinephrine content.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8738621     DOI: 10.1007/bf02550139

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  21 in total

1.  The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association.

Authors:  M J Barry; F J Fowler; M P O'Leary; R C Bruskewitz; H L Holtgrewe; W K Mebust; A T Cockett
Journal:  J Urol       Date:  1992-11       Impact factor: 7.450

2.  Catecholamine metabolism in pheochromocytoma and normal adrenal medullae.

Authors:  T Nakada; H Furuta; T Katayama
Journal:  J Urol       Date:  1988-12       Impact factor: 7.450

3.  Prazosin in the treatment of prostatic obstruction. A placebo-controlled study.

Authors:  R S Kirby; S W Coppinger; M O Corcoran; C R Chapple; M Flannigan; E J Milroy
Journal:  Br J Urol       Date:  1987-08

4.  Adrenergic innervation of the human testis, epididymis, ductus deferens and prostate: a fluorescence microscopic and fluorimetric study.

Authors:  H G Baumgarten; B Falck; A F Holstein; C Owman; T Owman
Journal:  Z Zellforsch Mikrosk Anat       Date:  1968

5.  Autonomic receptors in human prostate adenomas.

Authors:  D I Gup; E Shapiro; M Baumann; H Lepor
Journal:  J Urol       Date:  1990-01       Impact factor: 7.450

6.  Identification, quantification, and localization of mRNA for three distinct alpha 1 adrenergic receptor subtypes in human prostate.

Authors:  D T Price; D A Schwinn; J W Lomasney; L F Allen; M G Caron; R J Lefkowitz
Journal:  J Urol       Date:  1993-08       Impact factor: 7.450

7.  Alpha 1 adrenoceptor subtypes in the human prostate.

Authors:  H Lepor; R Tang; S Meretyk; E Shapiro
Journal:  J Urol       Date:  1993-03       Impact factor: 7.450

8.  The alpha-adrenoceptor subtype mediating the tension of human prostatic smooth muscle.

Authors:  H Lepor; R Tang; E Shapiro
Journal:  Prostate       Date:  1993       Impact factor: 4.104

9.  A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia.

Authors:  H Lepor; S Auerbach; A Puras-Baez; P Narayan; M Soloway; F Lowe; T Moon; G Leifer; P Madsen
Journal:  J Urol       Date:  1992-11       Impact factor: 7.450

10.  Effects of prazosin in patients with benign prostatic obstruction.

Authors:  H Hedlund; K E Andersson; A Ek
Journal:  J Urol       Date:  1983-08       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.